Bcr-Abl variants: Biological and clinical aspects

Leukemia Research

Volumn 26, Issue 8, 2002, Pages 713-720

  Advani, Anjali S ^a   Pendergast, Ann Marie ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute lymphocytic leukemia; Bcr Abl; Chronic myelogenous leukemia; Chronic neutrophilic leukemia; Philadelphia chromosome

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P185; PROTEIN P230; PROTEIN TYROSINE KINASE INHIBITOR; SCHH 6636; UNCLASSIFIED DRUG;

CHEMICAL STRUCTURE; CORRELATION ANALYSIS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0036280235     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00197-7     Document Type: Article

References (148)

1. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giesma staining
2. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
3. The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; However, SH2 signaling influences disease latency and phenotype
4. Chronic myeloid leukemia
5. Chronic myeloid leukemia
6. The biology of chronic myeloid leukemia
7. Chronic myelogenous leukemia: Update on biology and treatment
8. Chronic myelogenous leukemia: A concise update
9. Chronic myelogenous leukemia: A review
10. Characteristics of accelerated disease in chronic myelogenous leukemia
11. Differentiation patterns in the blastic phase of chronic myeloid leukemia
12. Chronic myelogenous leukemia in blast crisis: Analysis of 242 patients
13. Chronic myeloid leukemia from basics to bedside
14. Chronic myelogenous leukemia in the lymphoid blastic phase: Characteristics, treatment response, and prognosis
15. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor
16. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside
17. Therapy and prognostic factors in adult acute lymphoblastic leukemia
18. Clinical significance of molecular detection of the BCR-ABL fusion gene in acute lymphoblastic leukemia (ALL): A Cancer and Leukemia Group B (CALGB) study
19. Options for therapy in chronic myeloid leukaemia
20. Acute lymphoblastic leukemia
21. Philadelphia chromosome-positive leukemia: The translocated genes and their gene products
22. Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia
23. The significance of cytogenetic findings of erythroid colonies derived from a Ph+ ALL patient: Fundamental differences between Ph+ ALL and blastic CML
24. Difference of cell lineage expression of hematopoietic progenitor cells in Philadelphia-positive acute lymphoblastic leukemia and chronic myelogenous leukemia
25. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia
26. Molecular analysis of clonality and bcr rearrangements in Philadelphia chromosome-positive acute lymphoblastic leukemia
27. First intron and M-bcr breakpoints are restricted to the lymphoid lineage in Philadelphia positive acute lymphoblastic leukemia
28. Comparative biochemical and cytogenetic studies of childhood acute lymphoblastic leukemia with the Philadelphia chromosome and other 22q11 variants
29. Evidence for a multipotential stem cell in some childhood Philadelphia chromosome - Positive acute lymphoblastic leukemias
30. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker BCR/ABL with C3/A2 junction
31. A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis
32. Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia (letter)
33. Clonal nature of chronic neutrophilic leukemia (letter)
34. Bcr-Abl gene variants
35. P190 BCR-ABL chronic myeloid leukemia: The missing link with chronic myelomonocytic leukemia?
36. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia
37. Consistent amounts of acute leukemia-associated P190 BCR/ABL transcripts are expressed by chronic myelogenous leukemia pateints at diagnosis
38. BCR/ABL rearrangement and leukemia phenotype
39. P190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias
40. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients
41. Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukemia patients with a breakpoint around exon 14 (b3) of the BCR gene
42. Cytogenetic response to alpha-interferon is predicted in early chronic phase chronic myeloid leukemia by M-bcr breakpoint location
43. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukemia: No correlation with clinical features, cytogenetic response, duration of chronic phase, or survival
44. Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia
45. Analysis of the clinical relevance of the breakpoint location within M-bcr and the type of chimeric mRNA in chronic myelogenous leukemia
46. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia
47. Molecular analysis in chronic granulocytic leukemia: Location of breakpoints within M-bcr and relationship with presentation platelet counts
48. Molecular analysis of Philadelphia positive essential thrombocythemia
49. Ph-positive chronic myeloid leukemia mimicking essential thrombocythemia and termination into megakaryoblastic blast crisis: Report of two cases with molecular studies
50. Entire ABL gene is joined with 5′-BCR in some patients with Philadelphia-positive leukemia
51. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells
52. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein
53. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis
54. Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant
55. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1
56. Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase
57. Dominant negative MYC blocks transformation by ABL oncogenes
58. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia
59. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
60. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway
61. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation
62. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene
63. Factor independence of human myeloid leukemia cells is associated with increased phosphorylation of the proto-oncogene Raf-1
64. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
65. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway
66. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
67. A cytoplasmic inhibitor of the JNK signal transduction pathway
68. Dominant negative Myc blocks transformation by ABL oncogenes
69. Differential complementation of Bcr-Abl point mutants with c-Myc
70. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway
71. Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells
72. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
73. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
74. Abl tyrosine kinase in signal transduction and cell-cycle regulation
75. Signal transduction by wild-type and leukemogenic Abl proteins
76. Growth factor independence and BCR/ABL transformation: Promise and pitfalls of murine model systems and assays
77. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner
78. Mouse disabled (mDab1): A Src binding protein in neuronal development
79. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein
80. P62(dok): A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells
81. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl associated proteins
82. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells
83. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1
84. Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin
85. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase
86. Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants
87. Novel therapies for chronic myelogenous leukemia
88. Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL
89. Signaling by ABL oncogenes through cyclin D1
90. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity
91. Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia
92. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia
93. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
94. BCR-ABL: An anti-apoptosis gene in chronic myelogenous leukemia
95. In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome
96. Initiation of dysregulated growth of multipotent progenitor cells by bcr-abl in vitro
97. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation
98. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukemia
99. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia
100. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases
101. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
102. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity
103. Differences in tyrosine phosphorylated proteins between cells expressing P210bcr/abl and P190bcr/abl
104. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl
105. P210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
106. Rac, a novel ras-related family of proteins that are botulinum toxin substrates
107. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein
108. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia
109. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family
110. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
111. Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190 BCR-ABL or p210 BCR-ABL: Determination by analysis of individual colonies with the polymerase chain reaction
112. Cytogenetic studies of hemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukemia
113. Definition of the accelerated phase of chronic myelogenous leukemia
114. Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis
115. Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia
116. Biology of BCR-ABL
117. Mutations in the ras proto-oncogenes in chronic myelogenous leukemia: A high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia
118. P53 in chronic myelogenous leukemia in acute phase
119. The role of myc in transformation by BCR-ABL
120. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia
121. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia
122. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner
123. Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells
124. Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis
125. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
126. Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration
127. They cytogenetic scenario of chronic myeloid leukemia
128. Transforming genes in chronic myelogenous leukemia
129. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase
130. Chromosome abnormalities in malignant hematologic disease
131. Chronic myelogenous leukemia
132. Interferon-alfa versus chemotherapy for chronic myeloid leukemia: A meta-analysis of seven randomized trials
133. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT)
134. Polymerase chain reaction detection of the bcr-abl fusion transcript after allogeneic marrow transplantation for chronic meyloid leukemia - Results and implications in 346 patients
135. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon
136. Donor lymphocyte infusions
137. The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line
138. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
139. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
140. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
141. Phase I trial of specific abl tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients
142. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis
143. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia (letter)
144. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
145. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
146. Clinical resistance in STI-571 cancer treatment caused by Bcr-Abl gene mutation or amplification
147. BCR/ABL inhibition by an escort/phosphatase fusion protein. Proceedings of the National Academy of Sciences of the USA
148. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia